Two phase three studies suggest once-daily trifarotene 50 µg/g cream effectively and safely treats moderate facial and truncal acne.
Researchers reported on both 12-week double-blind, randomized, vehicle-controlled studies on people ages 9 years and older in a paper published June 2019 in the Journal of the American Academy of Dermatology (JAAD).1 The studies, called PERFECT 1 and PERFECT 2, included 200 sites in the United States, Canada, Europe and Russia and enrolled 2,420 patients with moderate facial and truncal acne who were treated with either trifarotene or vehicle.
Trifarotene (Galderma) is a retinoid receptor agonist that selectively targets retinoic acid receptor gamma (RAR-γ), which distinguishes it from other topical retinoids that target both retinoic acid receptor beta (RARβ) and RARγ, according to the paper.
“Trifarotene is pharmacokinetically stable in keratinocytes but is rapidly metabolized in hepatic microsomes, predicting a favorable safety profile; in addition, it has comedolytic, anti-inflammatory and anti-pigmenting properties,” the authors write.
The study design stands out because, while the pathophysiology and presentation of facial and truncal acne are thought to be similar, acne treatment options have not been vigorously studied on truncal acne, the authors write.
Disclosures: Nestle Skin Health Care-Galderma funded the phase 3 studies. Galderma employees were among the studies’ authors. Dr. Thiboutot was an investigator in the Phase 3 clinical trials for trifarotene at Penn State and attended one advisory meeting for trifarotene. She also served as an investigator for Botanix, Foamix and Cassiopea.
1 Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699.